Abstract
The aim of this study is to explore the differentially expressed lncRNAs, which may have potential biological function and diagnostic value in colorectal cancer (CRC). Through integrated data mining, we finally identified nine differentially expressed lncRNAs and their potential mRNA targets. After a series of bioinformatics analyses, we screened significant pathways and GO terms that are related to the up-regulated and down-regulated transcripts respectively. Meanwhile, the nine lncRNAs were validated in 30 paired tissues and cell lines by qRT-PCR and the results were basically consistent with the microarray data. We also tested the nine lncRNAs in the serum of 30 CRC patients matched with the CRC tissue, 30 non-cancer patients and 30 health controls. Finally, we found that BLACAT1 was significant for the diagnosis of CRC. The area under the curve (AUC), sensitivity and specificity were 0.858 (95% CI: 0.765–0.951), 83.3% and 76.7% respectively between CRC patients and health controls. Moreover, BLACAT1 also had distinct value to discriminate CRC from other non-cancer diseases. The results indicated that the differentially expressed lncRNAs and their potential target transcripts could be considered as potential therapeutic targets for CRC patients. Meanwhile, lncRNA BLACAT1 might represent a new supplementary biomarker for the diagnosis of CRC.
Highlights
LncRNA CRNDE was mainly reported to affect the biological characteristics of gliomas[44,45]
For lncRNA ZFAS1, there were two papers concerning colorectal cancer (CRC), among which one study reported that up-regulation predicted poor prognosis[46] while the other illuminated the interaction between ZFAS1 and Cyclin-dependent kinase 147
More and more research indicated that mutations and abnormal expression of lncRNAs were closely related to various cancers
Summary
LncRNA H19 was an independent prognostic factor and mediated methotrexate resistance in colorectal cancer through Wnt/β-catenin signal pathway[18,19] They are differential expression genes and play an important role in other cancers like glioma[20,21], ovarian cancer[22,23] and hepatic carcinoma[24,25]. A systematic expression profiling analysis was introduced to identify meta-signature lncRNAs between the CRC tissues and adjacent normal tissues. Bioinformatics analysis was adopted to further study the target genes and functional annotation of the differentially expressed lncRNAs, which might contribute to the research on targeted therapy of CRC. We detected the expression levels of lncRNAs in serum among CRC patients, non-cancer patients and health controls to find out novel biomarkers for the diagnosis and differentiation of CRC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
